Build vs buy dilemma: economics of manufacturing cell-based therapies

The cell and gene therapy industry’s push to resolve major bottlenecks in both manufacturing capacity and raw materials shortages has kept the build versus buy conversation center stage. It is vital that cell therapy developers and their investors revisit their manufacturing strategy, assess the pros and cons, and design new models to make these life-changing therapies a reality. Here, Dr Rupa Pike discusses the key considerations related to developing a strategic approach to cell therapy manufacturing.

Please enter your email to access content Read now